Acellera Clause Samples

Acellera. Acellera is playing a substantial role in three work packages, namely Biomedical Research Activities (WP2), Innovation and Sustainability (WP4), and Empowering Biomedical Applications (WP6). Acellera provide technology and knowhow for large-scale molecular simulations and analysis. They participate in the following research activities within the Molecular-based Medicine theme: Molecular simulation of the transport properties and mechanism of gating, to decipher the key factors controlling selectivity; Fragment-based drug design for GPCR targets; rational antibody design for EGFR inhibitors. Since the beginning of the project, Acellera participated in the dissemination of the project news and promoted the use of in silico methods in Industry and non-profit entities by participating and organising events, but especially by its effective marketing activity. This activity is illustrated by the organisation of workshops (10-11 Nov 2016, Barcelona, available at ▇▇▇.▇▇▇▇▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇?▇▇▇▇=▇▇▇▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇; 24th October 2017, Slough; 10-11 May 2018, Cambridge), its participation in the winter schools (14-16 February 2018 and 13-15 February 2019, Barcelona in collaboration with partner BSC), and the organisation of webinars exclusively for CompBioMed partners, namely "Cloud based MD simulations with AceCloud", 21-22 February 2018, and "PlayMolecule - on demand discovery platform", 21 March 2018, “HTMD” 23 March 2018) for CompBioMed partners, as well as webinars tailored for our customers. Strong in its expertise in biomolecular interactions, Acellera developed innovative methods to predict small molecule interaction with protein target, especially with GPCRs, in [5]. Acellera’s ISBA protocol, where ISBA stands for In Silico Binding Assay, has been optimized and is ready to initiate collaboration among CompBioMed partners. Moreover, they provide free access through its platform ▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ to promote the use of in silico methods for drug discovery and molecular medicine projects. Contacts have been initiated with ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ and UPF as well as Microsoft Azure to discuss collaboration on the use of the computational methods. Besides molecular dynamics simulations, ▇▇▇▇▇▇▇▇ embraced the use of machine learning applied to drug discovery and design. Started in 2016, the platform was released about a year after and shared with the scientific community for training and teaching purposes. After two years of development, it covers early aspects...